{"id":635040,"date":"2023-01-23T16:06:01","date_gmt":"2023-01-23T16:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=635040"},"modified":"2023-01-23T16:06:01","modified_gmt":"2023-01-23T16:06:01","slug":"diabetic-foot-ulcer-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-foot-ulcer-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_635040.html","title":{"rendered":"Diabetic Foot Ulcer Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1674452923.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Foot Ulcer Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1674452923.jpeg\" alt=\"Diabetic Foot Ulcer Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Diabetic Foot Ulcer Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s &#8216;Diabetic Foot Ulcer Pipeline Insight 2023&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Foot Ulcer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Foot Ulcer pipeline domain.<\/div>\n<p style=\"text-align: justify;\">United States, Nevada, Las Vegas, DelveInsight&rsquo;s <strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Diabetic Foot Ulcer Pipeline Insight 2023<\/strong><\/a><strong>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Foot Ulcer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Foot Ulcer pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Diabetic Foot Ulcer Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 34+ Diabetic Foot Ulcer pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetic Foot Ulcer market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Diabetic Foot Ulcer companies developing novel drug candidates to improve the Diabetic Foot Ulcer treatment landscape include<strong> Aurealis Therapeutics, Charsire Biotechnology Corporation, <\/strong>and others.<\/li>\n<li>Promising Diabetic Foot Ulcer pipeline therapies in various stages of development include<strong> AUP 16, CSTC 1, <\/strong>and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Diabetic Foot Ulcer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">A Diabetic Foot Ulcerss is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of Diabetic Foot Ulcersss requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.<\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Foot Ulcer Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>AUP 16: Aurealis Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\">AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector containing three therapeutic proteins (FGF2, IL4, and CSF1), produced continuously at the site of the wound, providing a combination biologic treatment in one product.<\/p>\n<p style=\"text-align: justify;\">Discover more about the emerging Diabetic Foot Ulcer drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Diabetic Foot Ulcer Treatment Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Foot Ulcer Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Aurealis Therapeutics<\/li>\n<li>Charsire Biotechnology Corporation<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Diabetic Foot Ulcer Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AUP 16<\/li>\n<li>CSTC 1<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Diabetic Foot Ulcer Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By development stage<\/strong><\/li>\n<li><strong>By product type<\/strong><\/li>\n<li><strong>By route of administration<\/strong><\/li>\n<li><strong>By molecule type<\/strong><\/li>\n<li><strong>By MOA type&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Diabetic Foot Ulcer Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Diabetic Foot Ulcer Companies<\/strong>: Aurealis Therapeutics, Charsire Biotechnology Corporation, and others<\/li>\n<li><strong>Key Diabetic Foot Ulcer Pipeline Therapies<\/strong>: AUP 16, CSTC 1, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out more about the Diabetic Foot Ulcer treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Diabetic Foot Ulcer Clinical Trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report to know more about the leading companies in the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/diabetic-foot-ulcers-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Diabetic Foot Ulcer pipeline domain<\/a>.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-foot-ulcer-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-foot-ulcer-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diabetic Foot Ulcer Pipeline Insights DelveInsight\u2019s &#8216;Diabetic Foot Ulcer Pipeline Insight 2023&#8217; report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Foot Ulcer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-foot-ulcer-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_635040.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-635040","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/635040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=635040"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/635040\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=635040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=635040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=635040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}